These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27708642)

  • 1. HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.
    Garrido C; Spivak AM; Soriano-Sarabia N; Checkley MA; Barker E; Karn J; Planelles V; Margolis DM
    Front Immunol; 2016; 7():356. PubMed ID: 27708642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    Garrido C; Tolstrup M; Søgaard OS; Rasmussen TA; Allard B; Soriano-Sarabia N; Archin NM; Margolis DM
    AIDS; 2019 Mar; 33(4):605-613. PubMed ID: 30830886
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Desimio MG; Giuliani E; Ferraro AS; Adorno G; Doria M
    Front Immunol; 2018; 9():1514. PubMed ID: 30008723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell toxicity of HIV latency reversing agents.
    Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
    Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells.
    Dimapasoc M; Moran JA; Cole SW; Ranjan A; Hourani R; Kim JT; Wender PA; Marsden MD; Zack JA
    Pathog Immun; 2024; 9(1):108-137. PubMed ID: 38765786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity
    Gramatica A; Schwarzer R; Brantley W; Varco-Merth B; Sperber HS; Hull PA; Montano M; Migueles SA; Rosenthal D; Hogan LE; Johnson JR; Packard TA; Grimmett ZW; Herzig E; Besnard E; Nekorchuk M; Hsiao F; Deeks SG; Snape M; Kiernan B; Roan NR; Lifson JD; Estes JD; Picker LJ; Verdin E; Krogan NJ; Henrich TJ; Connors M; Ott M; Pillai SK; Okoye AA; Greene WC
    J Virol; 2021 Mar; 95(8):. PubMed ID: 33536176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients?
    Martínez-Bonet M; Clemente MI; Serramía MJ; Moreno S; Muñoz E; Muñoz-Fernández MA
    J Virus Erad; 2015 Jul; 1(3):148-52. PubMed ID: 27482406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function.
    Sweeney EE; Balakrishnan PB; Powell AB; Bowen A; Sarabia I; Burga RA; Jones RB; Bosque A; Cruz CRY; Fernandes R
    Nano Res; 2020 Mar; 13(3):736-744. PubMed ID: 34079616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
    Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
    Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.
    Wu G; Swanson M; Talla A; Graham D; Strizki J; Gorman D; Barnard RJ; Blair W; Søgaard OS; Tolstrup M; Østergaard L; Rasmussen TA; Sekaly RP; Archin NM; Margolis DM; Hazuda DJ; Howell BJ
    JCI Insight; 2017 Aug; 2(16):. PubMed ID: 28814661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening.
    Divsalar DN; Simoben CV; Schonhofer C; Richard K; Sippl W; Ntie-Kang F; Tietjen I
    Front Pharmacol; 2020; 11():905. PubMed ID: 32625097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
    Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
    J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell responses to dendritic cells infected by the ANRS HIV-1 vaccine candidate, MVAHIV.
    Cummings JS; Moreno-Nieves UY; Arnold V; Gilbert A; Yarbrough K; Didier C; Lévy Y; Barré-Sinoussi F; Scott-Algara D;
    Vaccine; 2014 Sep; 32(43):5577-84. PubMed ID: 25131736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.
    Jønsson KL; Tolstrup M; Vad-Nielsen J; Kjær K; Laustsen A; Andersen MN; Rasmussen TA; Søgaard OS; Østergaard L; Denton PW; Jakobsen MR
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3984-94. PubMed ID: 25896701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells.
    Chan CN; Trinité B; Lee CS; Mahajan S; Anand A; Wodarz D; Sabbaj S; Bansal A; Goepfert PA; Levy DN
    Retrovirology; 2016 Jan; 13():1. PubMed ID: 26728316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.